System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Publications

Journal Article Review Epublish 6 citations

PubMed: 39861761 DOI: 10.3390/pharmaceutics17010114

Curcumin-Based Nanoparticles: Advancements and Challenges in Tumor Therapy.

Pharmaceutics 17(1)

Authors: Hicham Wahnou, Riad El Kebbaj, Bertrand Liagre, Vincent Sol, Youness Limami, Raphaƫl Emmanuel Duval

Affiliations

  • Laboratory of Immunology and Biodiversity, Faculty of Sciences Ain Chock, Hassan II University, B.P2693, Maarif, Casablanca 20100, Morocco.
  • Laboratory of Health Sciences and Technologies, Higher Institute of Health Sciences, Hassan First University of Settat, Settat 26000, Morocco.
  • Univ. Limoges, LABCiS, UR 22722, F-87000 Limoges, France.
  • UniversitĆ© de Lorraine, F-54000 Nancy, France.

Abstract

Curcumin, a bioactive compound derived from the rhizome of L., has garnered significant attention for its potent anticancer properties. Despite its promising therapeutic potential, its poor bioavailability, rapid metabolism, and low water solubility hinder curcumin's clinical application. Nanotechnology offers a viable solution to these challenges by enabling the development of curcumin-based nanoparticles (CNPs) that enhance its bioavailability and therapeutic efficacy. This review provides a comprehensive overview of the recent advancements in the design and synthesis of CNPs for cancer therapy. We discuss various NP formulations, including polymeric, lipid-based, and inorganic nanoparticles, highlighting their role in improving curcumin's pharmacokinetic and pharmacodynamic profiles. The mechanisms by which CNPs exert anticancer effects, such as inducing apoptosis, inhibiting cell proliferation, and modulating signaling pathways, are explored in details. Furthermore, we examine the preclinical and clinical studies that have demonstrated the efficacy of CNPs in treating different types of tumors, including breast, colorectal, and pancreatic cancers. Finally, the review addresses the current challenges and future perspectives in the clinical translation of CNPs, emphasizing the need for further research to optimize their design for targeted delivery and to enhance their therapeutic outcomes. By synthesizing the latest research, this review underscores the potential of CNPs as a promising avenue for advancing cancer therapy.

MeSH

Biological Availability, Nanoparticles, Neoplasms, Curcumin, Research, Therapeutics, Apoptosis

Cited by